Micro-cap biotech Nuvectis Pharma prices IPO at $5, the low end of the downwardly revised range
By Renaissance Capital Nuvectis Pharma, a Phase 1-ready biotech developing in-licensed precision therapies for cancer, raised $16 million by offering 3.2 million shares at $5, the low end of the downwardly revised range of $5 to $7. The company offered 1.1 million more shares than anticipated. It originally planned to offer 2.3 million shares at a[…]